H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Cuts Target Price to $4
Citius Pharmaceuticals Poised for Growth With Key Milestones and Promising Product Pipeline
Citius Pharmaceuticals Target Adjusted to $4 for Split at H.C. Wainwright
12 Health Care Stocks Moving In Tuesday's Intraday Session
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock
Express News | D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $9 Price Target
Citius Pharmaceuticals Analyst Ratings
8-K: Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals 1Q Rev $0.00 >CTXR
Citius Pharmaceuticals 1Q Loss/Shr $1.30 >CTXR
10-Q: Q1 2025 Earnings Report
Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Express News | Citius Pharma Announces LYMPHIR Is Approved By The FDA For The Treatment Of Adult Patients With Relapsed Or Refractory Stage 1-3 Cutaneous T-Cell Lymphoma
Express News | Citius Pharmaceuticals Inc: Permanent J-Code (J9161) Expected to Be Effective April 1, 2025
Express News | Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
10-K/A: Annual report (Amendment)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15%